See more : Molecule Holdings Inc. (EVRRF) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroPace, Inc. (NPCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroPace, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- China World Trade Center Co., Ltd. (600007.SS) Income Statement Analysis – Financial Results
- St. Augustine Gold and Copper Limited (SAU.TO) Income Statement Analysis – Financial Results
- Tianjin Jingwei Huikai Optoelectronic Co., Ltd. (300120.SZ) Income Statement Analysis – Financial Results
- Satin Creditcare Network Limited (SATIN.NS) Income Statement Analysis – Financial Results
- Real Estate Split Corp. (RS.TO) Income Statement Analysis – Financial Results
NeuroPace, Inc. (NPCE)
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 65.42M | 45.52M | 45.18M | 41.14M | 36.97M |
| Cost of Revenue | 17.30M | 13.03M | 11.75M | 10.87M | 10.51M |
| Gross Profit | 48.12M | 32.49M | 33.44M | 30.27M | 26.46M |
| Gross Profit Ratio | 73.56% | 71.38% | 74.00% | 73.59% | 71.58% |
| Research & Development | 20.78M | 21.95M | 18.21M | 15.70M | 18.29M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.52M | 51.34M | 38.96M | 27.63M | 30.20M |
| Other Expenses | 0.00 | -337.00K | -5.38M | 218.00K | 1.28M |
| Operating Expenses | 75.30M | 73.29M | 57.17M | 43.32M | 48.50M |
| Cost & Expenses | 92.60M | 86.31M | 68.92M | 54.19M | 59.00M |
| Interest Income | 3.05M | 1.58M | 448.00K | 41.00K | 261.00K |
| Interest Expense | 8.52M | 7.53M | 7.41M | 11.49M | 9.49M |
| Depreciation & Amortization | 1.61M | 2.99M | 296.00K | 312.00K | 421.00K |
| EBITDA | -22.83M | -36.57M | -28.37M | -12.48M | -20.07M |
| EBITDA Ratio | -34.90% | -86.89% | -62.80% | -30.34% | -54.28% |
| Operating Income | -27.17M | -40.79M | -23.74M | -13.05M | -22.03M |
| Operating Income Ratio | -41.54% | -89.62% | -52.54% | -31.72% | -59.59% |
| Total Other Income/Expenses | -5.78M | -6.29M | -12.34M | -11.23M | -7.94M |
| Income Before Tax | -32.96M | -47.08M | -36.08M | -24.28M | -29.97M |
| Income Before Tax Ratio | -50.38% | -103.43% | -79.85% | -59.02% | -81.07% |
| Income Tax Expense | 0.00 | 6.29M | 2.03M | 11.70M | 10.77M |
| Net Income | -32.96M | -53.37M | -38.11M | -35.98M | -40.74M |
| Net Income Ratio | -50.38% | -117.25% | -84.34% | -87.47% | -110.19% |
| EPS | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
| EPS Diluted | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
| Weighted Avg Shares Out | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
| Weighted Avg Shares Out (Dil) | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
NeuroPace to Report Fourth Quarter and Full Year 2021 Financial Results and Present at the 11th Annual SVB Leerink Global Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the fourth quarter and...
NeuroPace to Present at 40th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced that Mike Favet, CEO, Rebecca Kuhn, CFO and VP of...
NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q3 2021 Results - Earnings Call Transcript
NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q3 2021 Results - Earnings Call Transcript
NeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021
MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the third quarter of...
NeuroPace to Participate in Upcoming Conferences
MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported that the company will be participating in three upcoming conferences.
NeuroPace, Inc. (NPCE) CEO Mike Favet on Q2 2021 Results - Earnings Call Transcript
NeuroPace, Inc. (NPCE) CEO Mike Favet on Q2 2021 Results - Earnings Call Transcript
Could This Recently IPOed Medical Device Maker Make You Rich?
Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.
NeuroPace's (NPCE) CEO Mike Favet on Q1 2021 Results - Earnings Call Transcript
NeuroPace's (NPCE) CEO Mike Favet on Q1 2021 Results - Earnings Call Transcript
NeuroPace To Report First Quarter 2021 Financial Results on June 3, 2021
MOUNTAIN VIEW, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter of...
NeuroPace, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the closing of its initial...
Source: https://incomestatements.info
Category: Stock Reports